Zentiva Appeals EU Court Ruling on Urban Wastewater Treatment Directive

Zentiva Challenges European Court Decision on Urban Wastewater Treatment Directive

On April 28, 2026, Zentiva announced its appeal against a decision made by the European Court of Justice (ECJ) concerning the Urban Wastewater Treatment Directive (UWWTD). This appeal emerges from growing concerns surrounding the directive's implications on the availability and affordability of medications across Europe. Together with several other companies involved in the generic pharmaceutical sector, Zentiva aims to annul a previous ruling issued in March 2025 that deemed their legal challenge inadmissible.

The UWWTD has sparked significant unease among stakeholders, as conversations within the Employment, Social Policy, Health, and Consumer Affairs Council (EPSCO) revealed that 24 out of 27 EU member states expressed various levels of concern about the directive and its impact on the pharmaceutical market. Despite these apprehensions, the directive is currently being implemented at the national level, which many view as a threat to the access individuals have to vital medications.

Zentiva, known as a leading European manufacturer of generic drugs, recognizes the necessity for reducing micro-pollutants in municipal wastewater but firmly opposes the extended producer responsibility (EPR) element of the directive. The company argues that this stipulation places an unfair burden on pharmaceutical manufacturers by making them responsible for costs associated with pollutants not solely attributed to their products. This principle of holding producers liable for non-company-related waste undermines the fundamental ‘polluter pays’ doctrine.

The inherent risk this directive presents is significant: an increase in costs for generic medicines could lead to reduced availability for the millions who rely on them daily. The concerns are particularly highlighted as generics account for roughly 70% of all medicines dispensed in Europe and constitute nine out of ten drugs listed as essential by the EU. Steffen Saltofte, CEO of Zentiva and President of Medicines for Europe, emphasizes, "Generic medicines form the backbone of affordable healthcare in Europe. When disproportionate costs are imposed on essential medications, not only does supply become economically unviable, but patients ultimately bear the consequences. Protecting the environment must not come at the cost of public health."

Research has shown that the anticipated costs stemming from UWWTD are grossly underestimated, which could lead to future shortages of medications, escalating healthcare expenses, and a loss of competitiveness for the entire industry. It is troubling that the current regulatory framework does not incentivize the development of greener pharmaceuticals; rather, stringent time and resource constraints hinder the innovative rebirth of existing drugs, thereby failing to deliver the expected environmental benefits.

Zentiva's appeal seeks to overturn the ruling of inadmissibility that denied a hearing on the substantive elements of their case. By contesting Articles 9 and 10, in conjunction with Annex III of the UWWTD—which assigns at least 80% of costs related to what is termed quaternary sewage treatment to pharmaceutical producers—Zentiva aims to ensure adherence to the foundational legal principles of the European Union while protecting patient access to affordable medications.

Despite being directly impacted, Zentiva and its peers in the generic medicine sector have felt marginalized, unable to voice their arguments in court. Their appeal underscores a commitment to not only environmental stewardship but also to the core tenet of equitable healthcare access.

Moreover, Zentiva maintains its dedication to environmental sustainability, ranking among the top 2% in the pharmaceutical industry, as per EcoVadis 2025. The company manufactures, develops, and distributes high-quality affordable medications that cater to the health needs of over 100 million individuals across 40 countries in Europe. With four production sites and a broad network of external partners, Zentiva ensures a reliable supply chain while sustaining over 5,400 professionals dedicated to healthcare. For more information, you can visit Zentiva's official website or follow them on LinkedIn.